Muhammad Ali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Muhammad Ali has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Nadia Ahmed
Department of Sexual Health and HIV Central North West London NHS Foundation Trust London UK
1 shared publication Nathaniel Lee
UCL Hospitals NHS Trust, London, UK
1 shared publicationPatrick French
UCL Hospitals NHS Trust, London, UK
1 shared publicationRobert Miller
UCL Hospitals NHS Trust, London, UK
1 shared publication
Latest Publications
- 18 August 2023
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 34 (14) , 1072-1074
Effective prolonged suppression of HIV-1 viral load using tenofovir alafenamide, emtricitabine and efavirenz in an adult with BMI >59 kg/m2
Limited information is available regarding the efficacy of antiretrovirals in people with HIV-1 and high or very high Body Mass Index (BMI). This is especially the case for the alafenamide salt of tenofovir as clinical trials have only enrolled patients with BMI ≤30 kg/m2. Lower concentrations of some antiretrovirals are expected in patients with BMI >30 kg/m2 due to potential changes in clearance and distribution of medication. This report describes an individual taking tenofovir alafenamide, emtricitabine and efavirenz in whom HIV-1 viral load was consistently undetectable (2. Further data is required to support the efficacy of antiretrovirals in individuals with high and very high BMI.
- 18 August 2023
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 34 (14) , 1072-1074
Effective prolonged suppression of HIV-1 viral load using tenofovir alafenamide, emtricitabine and efavirenz in an adult with BMI >59 kg/m2
Limited information is available regarding the efficacy of antiretrovirals in people with HIV-1 and high or very high Body Mass Index (BMI). This is especially the case for the alafenamide salt of tenofovir as clinical trials have only enrolled patients with BMI ≤30 kg/m2. Lower concentrations of some antiretrovirals are expected in patients with BMI >30 kg/m2 due to potential changes in clearance and distribution of medication. This report describes an individual taking tenofovir alafenamide, emtricitabine and efavirenz in whom HIV-1 viral load was consistently undetectable (2. Further data is required to support the efficacy of antiretrovirals in individuals with high and very high BMI.